Erika Hamilton

Dr. Erika Hamilton, a medical oncologist at Sarah Cannon Research Institute, dives into the cutting-edge world of PROTAC estrogen receptor degraders for HR-positive metastatic breast cancer. She breaks down the differences between PROTACs and traditional therapies like SERDs, detailing their unique mechanisms and resistance advantages. The conversation highlights clinical trial data, tolerability issues, and the importance of precise biomarker testing. Erika also shares insights on future applications and the evolving landscape of treatment strategies for this challenging disease.

Join Dr. Erika Hamilton, a medical oncologist from the Sarah Cannon Research Institute, as she shares her expertise on groundbreaking breast cancer research from ASCO 2025. The discussion dives into the INAVO120 trial's survival benefits for specific patient groups, the promising results of SERENA-6 using ctDNA for better therapeutic decisions, and the significant progress shown in DESTINY-Breast09 and ASCENT-04 for treating advanced HER2-positive and triple-negative breast cancers. Explore the future of cancer treatment with these practice-changing insights!

Dr. Erika Hamilton, a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute, shares exciting insights about cancer care. She discusses the innovative digital tool, MyEye, which supports caregivers and enhances their quality of life. The conversation highlights groundbreaking research from upcoming presentations at the ASCO Annual Meeting, including advancements in targeted therapies for acute myeloid leukemia and significant findings on breast cancer treatment. Get ready for transformative changes in oncology!